Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Cedar Realty Trust reported total revenues of $20.2 million for the nine months ended September 30, 2026, a decrease from $21.7 million in the prior year period. The company achieved an operating income of $6.7 million for the first nine months of 2026, compared to $3.8 million in 2025, primarily due to the absence of impairment charges recorded in the previous year.
SunPower Inc. stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-35. The Board of Directors has the discretion to set the exact ratio or abandon the amendment. The approval occurred during the company's 2026 Annual Meeting, where shareholders also elected 11 directors and ratified BDO USA, P.C. as the independent auditor.
For the nine months ended September 30, 2026, SL Green reported a net loss attributable to common stockholders of $38.7 million, compared to a loss of $7.3 million in 2025. Total revenues increased to $790.1 million from $726.6 million, but the bottom line was impacted by higher operating expenses, interest costs, and depreciation.
Savers Value Village reported third quarter 2026 net sales of $463.1 million, an 8.5% increase driven by new store openings and 4.2% comparable store sales growth. The company expanded its ThriftIQ pricing platform to 108 stores and introduced new labor efficiency technology including a patent-pending Autotagger.
Term
13 weeks ended October 3, 2026
“We are proud of our strong third quarter results, which marked our fourth consecutive quarter of year-over-year adjusted EBITDA growth. We are pleased with continued strength in our U.S. business, encouraging signs of improvement in Canada, and stronger than expected profitability in our new stores.”
For the nine months ended September 30, 2026, SL Green reported a net loss attributable to common stockholders of $38.7 million, compared to a loss of $7.3 million in the prior year. Total revenues increased to $790.1 million, driven by higher rental and fee income, while the company recognized a significant gain on the sale of real estate totaling $103.9 million.
MannKind Corp reported total revenues of $101.9 million for the third quarter of 2026, a 24% increase year-over-year, driven by commercial product sales and royalties. However, the company swung to a net loss of $23.2 million for the quarter compared to a net income of $8.0 million in the prior year, primarily due to a significant increase in selling, general, and administrative expenses.
Bruker Corporation completed a reorganization of its reportable segments to streamline its organizational structure, effective July 1, 2026. The company recast its historical segment financial information for 2024, 2025, and 2026 to conform to the new structure, which now includes BSI BIOS and BSI Microbiology and Infection Diagnostics (BMID).
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher Barrett’s Esophagus test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
Term
Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
“Overall, our third-quarter results reflect the strength of our portfolio, consistent execution and continued progress toward our long-term growth objectives. I want to thank the entire Castle team for their dedication, hard work and unwavering commitment to improving patient care.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
Jacqueline Scanlan, Executive VP & Chief HRO, sold 4,930 shares of FMC Corp at $6.55 a share, worth $32.3K in total on Nov 3, 2026. Shares held after the trade: 58,628 (-7.8%).
Natera reported Q3 2026 total revenues of $794.0 million, a 34.1% increase year-over-year, driven by a 22.3% increase in total test volume. The company significantly raised its full-year 2026 revenue guidance by $140 million at the midpoint to a new range of $3.005 billion to $3.035 billion.
Fidus Investment Corporation reported Q3 2026 financial results with total investment income of $45.9 million and net investment income of $0.54 per share. The company's board also declared a total dividend of $0.54 per share for the fourth quarter, consisting of a $0.43 base and $0.11 supplemental dividend.
Term
Q3 2026
“In the third quarter, our high performing debt portfolio generated adjusted net investment income of $0.54, which represented 18% year over year growth driven by a 27% increase in interest income, and continued to amply cover our base dividend.”
Edward Ross, Chairman and CEO of Fidus Investment Corporation
“Looking ahead, we intend to continue to carefully select high quality companies that possess both defensive characteristics and positive outlooks for growth. Our proven investment strategy has served us well and positions Fidus to continue to deliver attractive risk-adjusted returns for our shareholders.”
Edward Ross, Chairman and CEO of Fidus Investment Corporation
Compass, Inc. reported record third-quarter 2026 results, with revenue increasing 112% year-over-year to $3.90 billion, driven by the integration of Anywhere. The company achieved GAAP net income of $62 million and record Adjusted EBITDA of $306 million, outperforming the broader housing market despite a year-over-year decline in industry transactions.
Term
Q3 2026
“In a housing market where transactions were down year-over-year, Compass delivered record financial and operational results in Q3. Adjusted EBITDA surpassed the high-end of our guidance range driven by solid OPEX discipline and ongoing cost synergy realization, while organic Brokerage GTV outperformed the market by 680 basis points on a pro forma basis.”
Robert Reffkin, Founder and Chief Executive Officer of Compass
“We are pleased with the results we delivered in a challenging environment with Q3 Revenue of $3.9 billion, GAAP Net income of $62 million and Adjusted EBITDA of $306 million, each reflecting all-time records for any third quarter in our history.”
For the nine months ended September 30, 2026, Runway Growth Finance Corp. reported total investment income of $107.0 million and net investment income of $44.7 million. The company experienced a significant net realized loss of $44.0 million, primarily from non-control/non-affiliate investments, resulting in a net increase in net assets from operations of $3.1 million compared to $26.7 million in the prior year period.
Incyte Principal Accounting Officer Thomas Tray Sells $72.6K of Stock
Thomas Tray, Principal Accounting Officer, sold 610 shares of Incyte Corp at $118.96 a share, worth $72.6K in total on Nov 3, 2026. Shares held after the trade: 21,126 (-2.8%).
Unusual Machines, Inc. reported a significant revenue increase to $38.7 million for the nine months ended September 30, 2026, compared to $6.3 million in the prior year, driven by acquisitions and expanded operations. However, the company recorded a net loss of $22.5 million for the period, primarily due to a $12.8 million unrealized loss on investments and increased general and administrative expenses.
Inspired Entertainment reported a net loss of $0.4 million for the nine months ended September 30, 2026, a significant improvement from the $9.8 million loss in the prior year period. Total revenue decreased to $179.4 million from $226.9 million, primarily due to lower service revenue, though the company achieved a positive comprehensive income of $4.1 million driven by favorable hedging instrument fair value changes.
Grayscale XRP Trust ETF reported a net decrease in net assets resulting from operations of $25.67 million for the nine months ended September 30, 2026, primarily driven by $34.23 million in net realized losses. The Trust's net assets decreased from $223.36 million at the end of 2025 to $97.42 million as of September 30, 2026, largely due to significant share redemptions totaling $180.78 million.
PRA Group reported Q3 2026 net income of $15 million and total cash collections of $536 million, driven by its PRA 3.0 strategy. The company achieved a 63% cash efficiency ratio and grew its estimated remaining collections (ERC) to $8.8 billion, up 5% year-over-year.
Term
Q3 2026
“Building on the positive momentum generated over the past year, we continued to execute against our PRA 3.0 strategy during the third quarter. We generated healthy cash collections, grew portfolio income, lowered operating expenses, and continued making disciplined portfolio investments, while achieving meaningful operational progress across many of our strategic initiatives.”
Martin Sjolund, President and Chief Executive Officer
“During the quarter, our adjusted cash efficiency ratio also improved by more than 200 basis points and Adjusted EBITDA continued to grow, reflecting the operating leverage we are beginning to realize from our cost reduction actions and broader PRA 3.0 initiatives.”
Martin Sjolund, President and Chief Executive Officer
Century Aluminum reported Q3 2026 net sales of $961.2 million, a sequential increase driven by higher shipments from the restart of Line 2 at its Grundartangi facility and favorable metal prices. Net income attributable to the company rose to $302.6 million, or $2.89 per diluted share, while liquidity remained strong at $1.16 billion.
Roper Technologies VP & CAO Brandon L. Cross Sells $979K of Stock
Brandon L. Cross, VP & CAO, sold 2,000 shares of Roper Technologies Inc at $489.30 a share, worth $979K in total on Nov 4, 2026. Shares held after the trade: 2,271 (-46.8%).
Vera Therapeutics reported its first quarter of commercial revenue following the July 2026 FDA accelerated approval of TRUTAKNA, generating $10.3 million in net product revenue. The company also completed its sBLA submission for full FDA approval and presented positive two-year Phase 3 ORIGIN data demonstrating a 76% reduction in kidney disease progression risk.
Term
Q3 2026
“We are excited by the early momentum of the TRUTAKNA launch, which exemplifies our long-standing confidence in its potential to become a foundational therapy in IgAN. Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN.”
Marshall Fordyce, M.D., Founder and Chief Executive Officer
“Our team is executing on the launch priorities we established for TRUTAKNA, with growing interest from the IgAN community and approximately 700 PSFs received since launch. We are encouraged by the payer coverage policies taking shape. Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.”
Ginkgo Bioworks reported Q3 2026 revenue of $28 million and a GAAP net loss of $41 million, showing improvement from the prior year's $73 million loss. The company highlighted the sale of its first autonomous lab to Novo and new government contracts with ARPA-H and the NSF as it transitions to a platform focused on Autonomous Labs and Cloud Lab services.
Term
Q3 2026
“Ginkgo now has two core offerings built on one autonomous lab platform. This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research.”
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
Medallion Financial Corp. reported net income attributable to the company of $2.4 million for the third quarter of 2026, down from $7.8 million in the prior year period, primarily due to a higher provision for credit losses. Total assets grew to $3.36 billion as of September 30, 2026, driven by an increase in the loan portfolio to $2.92 billion.
IonQ reported record Q3 2026 revenue of $173.8 million, a 336% year-over-year increase, and raised its full-year 2026 revenue guidance to a range of $505 million to $515 million. The company also announced the completion of its acquisition of cybersecurity firm Elisity for approximately 32.2 million shares of common stock to bolster its quantum security offerings.
Term
Q3 2026
“I am pleased to report that IonQ delivered its sixth consecutive quarter of record results and the strongest quarter in our company’s history. Third quarter revenue of $173.8 million reflects increasing demand for our quantum technologies and the benefits of our vertically integrated quantum manufacturing capabilities through SkyWater.”
BJ's Restaurants reported fiscal third quarter 2026 results featuring an 8.6% increase in total revenues to $358.6 million and an 8.1% rise in comparable restaurant sales. The company raised its full-year 2026 guidance for comparable sales and Adjusted EBITDA while continuing its share repurchase program with $84.5 million in remaining authorization.
Term
Q3 2026
“As we continue to make meaningful progress in our journey to unlock the full potential of this great brand, we delivered another strong quarter. The third quarter marked our ninth consecutive quarter of sales and traffic growth, with both comparable restaurant sales and traffic up approximately 8%, and our eighth quarter of profit growth, increasing restaurant level operating profit margin by 220 basis points year over year.”
Lyle Tick, Chief Executive Officer and President
“Looking ahead, we remain confident in our strategic growth drivers and will continue to invest in our team members, advance menu innovation that re-enforces compelling value and drives seasonal excitement, enhance the guest experience and ensure our 219 restaurants are places where our teams are proud to work and our guests are excited to return to.”
U.S. Physical Therapy, Inc. reported net revenue of $634.9 million for the nine months ended September 30, 2026, an increase from $578.3 million in the prior year. However, net income attributable to shareholders decreased to $26.0 million from $35.4 million, primarily due to higher operating costs and a loss on the change in fair value of contingent earn-out consideration.
Crimson Wine Group reported a significant increase in net sales to $60.7 million for the first nine months of 2026, up from $44.8 million in 2025, largely driven by the acquisition of the Raeburn Assets in February 2026. Despite the revenue growth, the company recorded a net loss of $1.3 million for the period due to higher operating expenses and interest costs associated with the acquisition financing.
aTyr Pharma reported third quarter 2026 financial results, ending the period with $50.3 million in cash and investments, providing a runway into late 2028. The company reached alignment with the FDA on a Phase 3 study protocol for efzofitimod in pulmonary sarcoidosis and is prioritizing strategic partnerships to advance the program.
“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need. We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships.”
Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
BJ’s Restaurants reported fiscal third quarter 2026 results with total revenues increasing 8.6% to $358.6 million and an 8.1% increase in comparable restaurant sales. The company raised its full-year 2026 guidance for comparable sales and Adjusted EBITDA while continuing its share repurchase program with $84.5 million remaining in authorization.
Term
Q3 2026
“The third quarter marked our ninth consecutive quarter of sales and traffic growth, with both comparable restaurant sales and traffic up approximately 8%, and our eighth quarter of profit growth, increasing restaurant level operating profit margin by 220 basis points year over year.”
Lyle Tick, Chief Executive Officer and President
“Looking ahead, we remain confident in our strategic growth drivers and will continue to invest in our team members, advance menu innovation that re-enforces compelling value and drives seasonal excitement, enhance the guest experience and ensure our 219 restaurants are places where our teams are proud to work and our guests are excited to return to.”
Civista Bancshares reported net income of $16.0 million for the third quarter of 2026, up from $12.8 million in the prior year period, driven by a significant increase in net interest income. Total assets decreased slightly to $4.3 billion as of September 30, 2026, while the company maintained a strong capital position despite an increase in accumulated other comprehensive loss due to unrealized losses on available-for-sale securities.